Machine Learning Models Cannot Replace Screening Colonoscopy for the Prediction of Advanced Colorectal Adenoma.
advanced adenoma
artificial intelligence
colorectal adenoma
colorectal cancer
machine learning
screening
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
29 Sep 2021
29 Sep 2021
Historique:
received:
23
08
2021
revised:
24
09
2021
accepted:
24
09
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
Screening for colorectal cancer (CRC) continues to rely on colonoscopy and/or fecal occult blood testing since other (non-invasive) risk-stratification systems have not yet been implemented into European guidelines. In this study, we evaluate the potential of machine learning (ML) methods to predict advanced adenomas (AAs) in 5862 individuals participating in a screening program for colorectal cancer. Adenomas were diagnosed histologically with an AA being ≥ 1 cm in size or with high-grade dysplasia/villous features being present. Logistic regression (LR) and extreme gradient boosting (XGBoost) algorithms were evaluated for AA prediction. The mean age was 58.7 ± 9.7 years with 2811 males (48.0%), 1404 (24.0%) of whom suffered from obesity (BMI ≥ 30 kg/m²), 871 (14.9%) from diabetes, and 2095 (39.1%) from metabolic syndrome. An adenoma was detected in 1884 (32.1%), as well as AAs in 437 (7.5%). Modelling 36 laboratory parameters, eight clinical parameters, and data on eight food types/dietary patterns, moderate accuracy in predicting AAs with XGBoost and LR (AUC-ROC of 0.65-0.68) could be achieved. Limiting variables to established risk factors for AAs did not significantly improve performance. Moreover, subgroup analyses in subjects without genetic predispositions, in individuals aged 45-80 years, or in gender-specific analyses showed similar results. In conclusion, ML based on point-prevalence laboratory and clinical information does not accurately predict AAs.
Identifiants
pubmed: 34683122
pii: jpm11100981
doi: 10.3390/jpm11100981
pmc: PMC8538127
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
JAMA Cardiol. 2021 Jun 1;6(6):633-641
pubmed: 33688915
Gut. 2007 Nov;56(11):1585-9
pubmed: 17591622
JAMA. 2016 Jun 21;315(23):2576-94
pubmed: 27305422
BMC Med. 2021 Jan 4;19(1):1
pubmed: 33390155
Clin Cancer Res. 2016 Apr 1;22(7):1725-33
pubmed: 26561557
Int J Cancer. 2012 Jun 15;130(12):2961-73
pubmed: 21792895
Int J Med Inform. 2021 Jan;145:104312
pubmed: 33126059
JAMA. 2011 Sep 28;306(12):1352-8
pubmed: 21954479
Trends Microbiol. 2020 May;28(5):401-423
pubmed: 32298617
JAMA. 2018 May 15;319(19):2021-2031
pubmed: 29800214
World J Gastroenterol. 2018 Jan 7;24(1):124-138
pubmed: 29358889
Am J Gastroenterol. 2018 Dec;113(12):1788-1800
pubmed: 30315282
Clin Gastroenterol Hepatol. 2019 Sep;17(10):1969-1981.e15
pubmed: 30659991
Am J Prev Med. 2010 May;38(5):508-16
pubmed: 20409499
Gut. 2018 Feb;67(2):291-298
pubmed: 27733426
Sci Rep. 2021 Sep 7;11(1):17785
pubmed: 34493755
Br J Cancer. 2016 Nov 22;115(11):1421-1429
pubmed: 27764840
Cell. 2020 Apr 2;181(1):92-101
pubmed: 32243801
Gastroenterology. 2019 Jul;157(1):137-148
pubmed: 30930021
Gut. 2017 Apr;66(4):683-691
pubmed: 26818619
N Engl J Med. 2013 Sep 19;369(12):1095-105
pubmed: 24047059
PLoS One. 2020 Dec 31;15(12):e0244514
pubmed: 33382757
Am J Hum Genet. 2020 Sep 3;107(3):432-444
pubmed: 32758450
Gut. 2019 Apr;68(4):672-683
pubmed: 29615487
Endoscopy. 2013;45(1):51-9
pubmed: 23212726
J Gastroenterol Hepatol. 2012 Jun;27(6):1070-7
pubmed: 22004224
Br J Cancer. 2018 Mar 6;118(5):750-759
pubmed: 29381683
Am J Gastroenterol. 2019 Sep;114(9):1520-1530
pubmed: 31464746